NCT06362967View on ClinicalTrials.gov

The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
High Titers of Anti-HLA Antibody (MFI ≥5000)
Interventions
COMBINATION_PRODUCT

Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG

For allogeneic haematopoietic stem cell transplantation patients with high titers of anti-HLA antibodies present in the body, a desensitisation regimen of immunosorbent or plasma exchange combined with rituximab and high-dose IVIG is used prior to transplantation.

Trial Locations (1)

230036

RECRUITING

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV